secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053928
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics Q1 net loss $98.7M; BEAM-101 expansion cohort opened, cash $1.1B into 2027
--------------------------------------------------------------------------------

- Net loss of $98.7M ($1.21 per share) vs $96.5M ($1.33 per share) in Q1 2023.
- Cash, cash equivalents and marketable securities $1.1B as of March 31, 2024; runway into 2027.
- R&D expenses $84.8M, G&A expenses $26.7M for Q1 2024.
- BEAM-101 BEACON trial sentinel cohort dosing completed; expansion cohort initiated with up to 45 patients.
- BEAM-302 CTA cleared in UK for Phase 1/2 in AATD; BEAM-301 IND submission on track for H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024053928/0000950170-24-053928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017024053928/beam-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer